82982-54-5

Basic information

• Product Name: Ethanone, 2-bromo-1-(5-methyl-1H-imidazol-4-yl)- (9CI)
• Synonyms: Ethanone, 2-bromo-1-(5-methyl-1H-imidazol-4-yl)- (9CI)
• CAS NO: 82982-54-5
• Molecular Formula: C6H7BrN2O
• Molecular Weight: 203.03658
• Product Categories: ACETYLHALIDE
• Mol File: 82982-54-5.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethanone, 2-bromo-1-(5-methyl-1H-imidazol-4-yl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 2-bromo-1-(5-methyl-1H-imidazol-4-yl)- (9CI)(82982-54-5)
• EPA Substance Registry System: Ethanone, 2-bromo-1-(5-methyl-1H-imidazol-4-yl)- (9CI)(82982-54-5)

Safety Data

• Hazardous Substances Data: 82982-54-5(Hazardous Substances Data)

Usage

General Description

Ethanone, 2-bromo-1-(5-methyl-1H-imidazol-4-yl)- (9CI) is a chemical compound with the molecular formula C7H7BrN2O. It is also known by its IUPAC name 1-(5-methyl-1H-imidazol-4-yl)-2-bromoethanone. Ethanone, 2-bromo-1-(5-methyl-1H-imidazol-4-yl)- (9CI) contains a bromine atom, a carbonyl group, and an imidazole ring, making it a ketone with a bromo-substituted imidazole moiety. It is used in pharmaceutical research and development, particularly in the synthesis of potential drug candidates targeting imidazole receptors or related biological functions. Ethanone, 2-bromo-1-(5-methyl-1H-imidazol-4-yl)- (9CI) may also be used in organic chemistry reactions and as a building block for the preparation of other chemical compounds. Its unique structure and functional groups make it a valuable reagent in synthetic chemistry.

Upstream product

• 23328-91-8 1H-5-Acetyl-4-methylimidazole 
• 29917-12-2 Isonitrosoacetylacetone 
• 74337-16-9 4-acetyl-5-methyl-4-imidazoline-2-thione 
• 23328-91-8 methyl 5⁽⁴⁾-methylimidazole-4⁽⁵⁾-yl ketone 

Relevant articles and documents

4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases

This invention is directed to aminothiazole compounds of formula (I) wherein R1 is a substituted or unsubstituted group selected from : C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl; (C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol, thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; or a pharmaceutically acceptable salt of a compound of formula (I), or a prodrug or pharmaceutically active metabolite of a compound of formula (I) or pharmaceutically acceptable salt thereof, for inhibiting cyclin-dependent kinases (CDKs), such as CDK1, CDK2, CDK4, and CDK6. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.